Proteomics uncovers molecular features for relapse risk stratification in patients with diffuse large B-cell lymphoma

Blood Cancer J. 2023 Oct 26;13(1):161. doi: 10.1038/s41408-023-00931-6.

Maja Ludvigsen^{1

2}, Amanda Jessica Campbell³, Marie Beck Enemark^{4

3}, Trine Engelbrecht Hybel^{4

3}, Marja-Liisa Karjalainen-Lindsberg⁵, Klaus Beiske⁶, Mette Bjerre⁷, Lars Møller Pedersen⁸, Harald Holte^{9

10

11}, Sirpa Leppä^{12

13

14}, Judit Meszaros Jørgensen^#⁴, Bent Honoré^#¹⁵

¹ Department of Hematology, Aarhus University Hospital, Aarhus, Denmark. majlud@rm.dk.
² Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. majlud@rm.dk.
³ Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
⁴ Department of Hematology, Aarhus University Hospital, Aarhus, Denmark.
⁵ Department of Pathology, Helsinki University Hospital, Helsinki, Finland.
⁶ Department of Pathology, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway.
⁷ Medical/Steno Aarhus Research Laboratory, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
⁸ Zealand University Hospital, Roskilde, Denmark.
⁹ Department of Oncology, Oslo University Hospital, Oslo, Norway.
¹⁰ KG Jebsen Center for B-Cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
¹¹ Norwegian Cancer Genomics Consortium, Oslo, Norway.
¹² Research Program Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
¹³ Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
¹⁴ iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland.
¹⁵ Department of Biomedicine, Aarhus University, Aarhus, Denmark. bh@biomed.au.dk.

^# Contributed equally.

No abstract available

Publication types